IL280563B2 - נוגדנים כנגד btn3a ושימושיהם לטיפול בסרטן ומחלות מדבקות - Google Patents

נוגדנים כנגד btn3a ושימושיהם לטיפול בסרטן ומחלות מדבקות

Info

Publication number
IL280563B2
IL280563B2 IL280563A IL28056321A IL280563B2 IL 280563 B2 IL280563 B2 IL 280563B2 IL 280563 A IL280563 A IL 280563A IL 28056321 A IL28056321 A IL 28056321A IL 280563 B2 IL280563 B2 IL 280563B2
Authority
IL
Israel
Prior art keywords
antibody
cells
btn3a
mab1
cell
Prior art date
Application number
IL280563A
Other languages
English (en)
Other versions
IL280563B1 (he
IL280563A (he
Inventor
Truneh Alemseged
Olive Daniel
Pasero Christine
DE GASSART Aude
Original Assignee
Imcheck Therapeutics Sas
Inst Nat Sante Rech Med
Univ Aix Marseille
Inst Jean Paoli & Irene Calmette
Centre Nat Rech Scient
Truneh Alemseged
Olive Daniel
Pasero Christine
DE GASSART Aude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcheck Therapeutics Sas, Inst Nat Sante Rech Med, Univ Aix Marseille, Inst Jean Paoli & Irene Calmette, Centre Nat Rech Scient, Truneh Alemseged, Olive Daniel, Pasero Christine, DE GASSART Aude filed Critical Imcheck Therapeutics Sas
Publication of IL280563A publication Critical patent/IL280563A/he
Publication of IL280563B1 publication Critical patent/IL280563B1/he
Publication of IL280563B2 publication Critical patent/IL280563B2/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL280563A 2018-08-01 2019-07-31 נוגדנים כנגד btn3a ושימושיהם לטיפול בסרטן ומחלות מדבקות IL280563B2 (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306050 2018-08-01
EP19153992 2019-01-28
PCT/EP2019/070693 WO2020025703A1 (en) 2018-08-01 2019-07-31 Anti-btn3a antibodies and their use in treating cancer or infectious disorders

Publications (3)

Publication Number Publication Date
IL280563A IL280563A (he) 2021-03-25
IL280563B1 IL280563B1 (he) 2024-06-01
IL280563B2 true IL280563B2 (he) 2024-10-01

Family

ID=67470408

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280563A IL280563B2 (he) 2018-08-01 2019-07-31 נוגדנים כנגד btn3a ושימושיהם לטיפול בסרטן ומחלות מדבקות

Country Status (22)

Country Link
US (3) US11987631B2 (he)
EP (2) EP3830119B1 (he)
JP (3) JP7401166B2 (he)
KR (2) KR20260053570A (he)
CN (2) CN118459590A (he)
AU (2) AU2019312831B2 (he)
BR (1) BR112021001776A2 (he)
CA (2) CA3275403A1 (he)
CL (1) CL2021000258A1 (he)
DK (1) DK3830119T3 (he)
ES (1) ES3060430T3 (he)
FI (1) FI3830119T3 (he)
HR (1) HRP20260034T1 (he)
IL (1) IL280563B2 (he)
LT (1) LT3830119T (he)
MX (1) MX2021001268A (he)
RS (1) RS67711B1 (he)
SG (1) SG11202101038SA (he)
SI (1) SI3830119T1 (he)
SM (1) SMT202600072T1 (he)
WO (1) WO2020025703A1 (he)
ZA (1) ZA202100819B (he)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3013333A1 (en) * 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
EP3830119B1 (en) * 2018-08-01 2025-11-12 Imcheck Therapeutics Anti-btn3a antibodies and their use in treating cancer or infectious disorders
CA3222934A1 (en) * 2021-06-18 2022-12-22 Therini Bio, Inc. Antibodies which bind human fibrin or fibrinogen yc domain and methods of use
TW202313695A (zh) 2021-09-15 2023-04-01 法商感應檢查療法公司 抗ｂｔｎ３ａ抗體在製備用於治療腫瘤的藥物的用途
WO2023052541A1 (en) 2021-09-30 2023-04-06 Imcheck Therapeutics Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
EP4423132A1 (en) 2021-10-27 2024-09-04 Imcheck Therapeutics Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders
KR20240149438A (ko) 2022-02-27 2024-10-14 베링거 인겔하임 인터내셔날 게엠베하 Cd277 및 종양-항원에 대한 이중특이적 항체
CA3266717A1 (en) 2022-10-04 2024-04-11 Institut Jean Paoli & Irene Calmettes COMBINATION OF A BTN3A ACTIVATING ANTIBODY, A BCL2 INHIBITOR AND A HYPOMETHYLATING AGENT INTENDED FOR USE IN THE TREATMENT OF CANCER
JP2026506893A (ja) 2023-02-23 2026-02-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ３ａ活性化抗体と免役チェックポイント阻害剤の併用
TW202506731A (zh) 2023-04-27 2025-02-16 法商感應檢查療法公司 治療多重抗藥性細菌感染之方法
EP4731681A1 (en) 2023-06-23 2026-04-29 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2025031287A1 (zh) 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 Btn3a结合蛋白及其医药用途
WO2025223116A1 (en) * 2024-04-24 2025-10-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-btn3a antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080351A1 (en) * 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
US20150353643A1 (en) * 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
EP3002296B1 (en) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla antibodies and uses thereof
IN2012DN00863A (he) 2009-07-31 2015-07-10 Medarex Inc
KR101831229B1 (ko) 2009-09-06 2018-02-22 프로탭 리미티드 Ｈｓｐ65-유도 펩티드-6에 특이한 인간화 항체, 그것의 방법 및 용도
MX343376B (es) * 2010-07-15 2016-11-03 Adheron Therapeutics Inc Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados.
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
IL252131B2 (he) 2014-11-17 2023-04-01 Adicet Bio Inc תאי–t גמא דלתא מהונדסים
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
EP3830119B1 (en) * 2018-08-01 2025-11-12 Imcheck Therapeutics Anti-btn3a antibodies and their use in treating cancer or infectious disorders
TW202313695A (zh) * 2021-09-15 2023-04-01 法商感應檢查療法公司 抗ｂｔｎ３ａ抗體在製備用於治療腫瘤的藥物的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080351A1 (en) * 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
US20150353643A1 (en) * 2013-09-24 2015-12-10 Universite De La Mediterranee - Aix-Marseille Ii Anti-cd277 antibodies and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AUDREY BENYAMINE ET AL:, BTN3A MOLECULES CONSIDERABLY IMPROVE V[GAMMA]9V[DELTA]2T CELLS-BASED IMMUNOTHERAPY IN ACUTE MYELOID LEUKEMIA, 2 October 2016 (2016-10-02) *
AUDREY D MCCONNELL ET AL:, A GENERAL APPROACH TO ANTIBODY THERMOSTABILIZATION, 3 September 2014 (2014-09-03) *
BENYAMINE AUDREY ET AL:, BTN3A IS A PROGNOSIS MARKER AND A PROMISING TARGET FOR V[GAMMM]9V[DELTA]2T CELLS BASED- IMMUNOTHERAPY IN PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), 31 August 2017 (2017-08-31) *
DAVID GARETH WILLIAMS ET AL:, HUMANISING ANTIBODIES BY CDR GRAFTING" IN: " ANTIBODY ENGINEERING, 1 January 2010 (2010-01-01) *
JUAN-LUIS BLAZQUEZ ET AL:, NEW INSIGHTS INTO THE REGULATION OF [GAMMA][DELTA] T CELLS BY BTN3A AND OTHER BTN/BTNL IN TUMOR IMMUNITY, 11 July 2018 (2018-07-11) *
ROUET ROMAIN ET AL:, STABILITY ENGINEERING OF THE HUMAN ANTIBODY REPERTOIRE, 28 November 2013 (2013-11-28) *
STEFAN EWERT ET AL:, STABILITY IMPROVEMENT OF ANTIBODIES FOR EXTRACELLULAR AND INTRACELLULAR APPLICATIONS: CDR GRAFTING TO STABLE FRAMEWORKS AND STRUCTURE-BASED FRAMEWORK ENGINEERING, 1 October 2004 (2004-10-01) *
SUMIT GOSWAMI ET AL:, DEVELOPMENTS AND CHALLENGES FOR MAB-BASED THERAPEUTICS, 16 August 2013 (2013-08-16) *
TAEK-KEUN KIM ET AL:, INHIBITION OF VEGF-DEPENDENT ANGIOGENESIS AND TUMOR ANGIOGENESIS BY AN OPTIMIZED ANTIBODY TARGETING CLEC14A, 26 January 2018 (2018-01-26) *

Also Published As

Publication number Publication date
CN113286819A (zh) 2021-08-20
AU2019312831A1 (en) 2021-02-18
CA3275403A1 (en) 2026-03-02
IL280563B1 (he) 2024-06-01
HRP20260034T1 (hr) 2026-02-27
ZA202100819B (en) 2022-09-28
DK3830119T3 (da) 2026-02-02
US20230272080A1 (en) 2023-08-31
JP2024028834A (ja) 2024-03-05
EP3830119A1 (en) 2021-06-09
EP3830119B1 (en) 2025-11-12
SG11202101038SA (en) 2021-02-25
SMT202600072T1 (it) 2026-03-09
RS67711B1 (sr) 2026-02-27
AU2019312831B2 (en) 2025-08-14
WO2020025703A1 (en) 2020-02-06
AU2025259841A1 (en) 2025-11-20
KR102949202B1 (ko) 2026-04-08
FI3830119T3 (fi) 2026-01-23
CN113286819B (zh) 2024-05-24
US11987631B2 (en) 2024-05-21
CL2021000258A1 (es) 2021-07-02
JP7825605B2 (ja) 2026-03-06
CA3107933A1 (en) 2020-02-06
EP4650007A3 (en) 2026-02-25
ES3060430T3 (en) 2026-03-26
LT3830119T (lt) 2026-02-25
BR112021001776A2 (pt) 2021-05-04
US20230322932A1 (en) 2023-10-12
EP4650007A2 (en) 2025-11-19
JP7401166B2 (ja) 2023-12-19
SI3830119T1 (sl) 2026-03-31
JP2026016397A (ja) 2026-02-03
KR20210084426A (ko) 2021-07-07
MX2021001268A (es) 2021-09-08
KR20260053570A (ko) 2026-04-21
CN118459590A (zh) 2024-08-09
US11945871B2 (en) 2024-04-02
US20220112289A1 (en) 2022-04-14
IL280563A (he) 2021-03-25
JP2021533204A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
US11945871B2 (en) Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
US20250270324A1 (en) Antibody molecules
JP6703520B2 (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
KR20200061402A (ko) 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합
KR20200131286A (ko) 종양 특이적 세포 고갈에 대한 항-cd25
US12247075B2 (en) BTN3A binding proteins and uses thereof
KR102887991B1 (ko) 이중특이적 항pd-1 tim3 항체
US12570757B2 (en) Antibodies against the poliovirus receptor (PVR) and uses thereof
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
HK40054235B (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders
HK40054235A (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders
RU2800726C2 (ru) Антитела против btn3a и их применение при лечении рака или инфекционных заболеваний
RU2812910C2 (ru) Антитела к cd38 и комбинации с антителами к cd3 и cd28
RU2815066C2 (ru) Молекулы, связывающие мезотелин и cd137
TW202448504A (zh) Btn3a活化抗體及免疫檢查點抑制劑之組合